Pre-made Bentracimab benchmark antibody ( Whole mAb, anti-AR-C124910XX therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Bentracimab biosimilar, Whole Mab: Anti-AR-C124910XX therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Bentracimab is a monoclonal antibody medication which has been shown in phase one and two clinical trials to function as a reversal agent for the anti-blood clotting drug ticagrelor (which acts as a P2Y12 inhibitor and is sold under the brand name Brilinta among others).[2] It is under investigation for use in major, life-threatening bleeding in patients being treated with ticagrelor.[3] It is not commercially available.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-059-1mg	1mg	3090
GMP-Bios-ab-059-10mg	10mg	Inquiry
GMP-Bios-ab-059-100mg	100mg	Inquiry
GMP-Bios-ab-059-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Bentracimab biosimilar, Whole Mab: Anti-AR-C124910XX therapeutic antibody
INN Name	Bentracimab
Target	AR-C124910XX
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Active
100% SI Structure	5alb:HL
99% SI Structure	None
95-98% SI Structure	5alc:HL
Year Proposed	2020
Year Recommended	2021
Companies	MedImmune;AstraZeneca;PhaseBio
Conditions Approved	na
Conditions Active	Haemorrhage (reversal of effects of ticagrelor)
Conditions Discontinued	na
Development Tech	na